Meeting
2023 ASCO Annual Meeting
A theranostic approach: Imaging and therapy of delta-like ligand 3–expressing small cell lung cancers.
Authors
Salomon Tendler
Memorial Sloan Kettering Cancer Center, New York, NY
Salomon Tendler , David Bauer , Joshua Korsen , Alexa Michel , Roberto Degregorio , Lukas Carter , Nagavarakishore Pillarsetty , John T. Poirier , Jason Stuart Lewis , Charles M. Rudin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8575)
DOI
10.1200/JCO.2023.41.16_suppl.8575
Abstract #
8575
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).
First Author: Lauren Averett Byers
Poster
2017 ASCO Annual Meeting
Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC).
First Author: Loredana Puca
Poster
2024 ASCO Breakthrough
Differential expression in potential therapeutic target protein by treatment in small cell lung cancer with and without transformation.
First Author: Saori Murata
Poster
2024 ASCO Annual Meeting
Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).
First Author: Himisha Beltran